Cesca Therapeutics Inc. (NASDAQ:KOOL) has been assigned a consensus broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation.

Zacks has also assigned Cesca Therapeutics an industry rank of 171 out of 265 based on the ratings given to its competitors.

Separately, ValuEngine lowered Cesca Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th.

Cesca Therapeutics (KOOL) opened at $2.94 on Friday. Cesca Therapeutics has a fifty-two week low of $2.41 and a fifty-two week high of $6.44. The company has a current ratio of 2.06, a quick ratio of 1.23 and a debt-to-equity ratio of 0.16.

ILLEGAL ACTIVITY WARNING: “Zacks: Cesca Therapeutics Inc. (KOOL) Given Consensus Rating of “Hold” by Brokerages” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/zacks-cesca-therapeutics-inc-kool-given-consensus-rating-of-hold-by-brokerages/1740619.html.

About Cesca Therapeutics

Cesca Therapeutics Inc is clinical-stage biotechnology company. The Company develops and markets integrated cellular therapies and delivery systems. The Company is engaged in developing and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.

Get a free copy of the Zacks research report on Cesca Therapeutics (KOOL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cesca Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.